It’s been almost a decade since the release of the first stunning data on a cell therapy that battled blood cancer by genetically altering a patient’s own white blood cells to attack it. Many years and billions of dollars in mergers and acquisitions later, CAR-T is still used mostly as a last resort. Could new clinical trials that are about to report out in full change that?
Join us October 14 at 1-2 PM ET, as President of Project Farma and Precision ADVANCE Anshul Mangal joins STAT in welcoming industry experts to speak on the evolution of cell-based immunotherapy considering recent clinical trials data in this insightful panel discussion hosted by STAT and sponsored by Precision ADVANCE.